X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (133764) 133764
Magazine Article (182) 182
Transcript (36) 36
Newsletter (35) 35
Publication (34) 34
Newspaper Article (23) 23
Book / eBook (22) 22
Book Review (10) 10
Book Chapter (7) 7
Conference Proceeding (5) 5
Dissertation (5) 5
Web Resource (4) 4
Reference (3) 3
Government Document (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (130011) 130011
antineoplastic combined chemotherapy protocols - therapeutic use (107070) 107070
female (83342) 83342
male (68858) 68858
middle aged (64104) 64104
oncology (62482) 62482
adult (53008) 53008
aged (52708) 52708
chemotherapy (38881) 38881
treatment outcome (33197) 33197
cancer (30324) 30324
combined modality therapy (25949) 25949
antineoplastic combined chemotherapy protocols - adverse effects (24978) 24978
prognosis (21570) 21570
neoplasm staging (18749) 18749
cisplatin - administration & dosage (17741) 17741
aged, 80 and over (15454) 15454
hematology (15306) 15306
survival rate (15099) 15099
antineoplastic agents - therapeutic use (14615) 14615
adolescent (14435) 14435
retrospective studies (14151) 14151
disease-free survival (13893) 13893
fluorouracil - administration & dosage (13693) 13693
therapy (13436) 13436
care and treatment (13297) 13297
breast neoplasms - drug therapy (12836) 12836
antineoplastic combined chemotherapy protocols - administration & dosage (12558) 12558
doxorubicin - administration & dosage (12544) 12544
follow-up studies (12453) 12453
cyclophosphamide - administration & dosage (12345) 12345
survival analysis (12233) 12233
animals (12151) 12151
survival (12055) 12055
lung neoplasms - drug therapy (11914) 11914
chemotherapy, adjuvant (11338) 11338
drug administration schedule (10943) 10943
cisplatin (10520) 10520
medicine & public health (10401) 10401
remission induction (10129) 10129
child (9982) 9982
surgery (9449) 9449
radiotherapy (8976) 8976
vincristine - administration & dosage (8844) 8844
research (8665) 8665
carcinoma (8447) 8447
tumors (8329) 8329
breast cancer (7907) 7907
pharmacology & pharmacy (7829) 7829
analysis (7737) 7737
trial (7730) 7730
time factors (7326) 7326
mice (7288) 7288
breast neoplasms - pathology (7278) 7278
deoxycytidine - analogs & derivatives (7244) 7244
etoposide - administration & dosage (7160) 7160
metastasis (7096) 7096
prospective studies (7078) 7078
hematology, oncology and palliative medicine (7049) 7049
child, preschool (7035) 7035
cell line, tumor (7008) 7008
carcinoma, non-small-cell lung - drug therapy (6896) 6896
clinical trials as topic (6676) 6676
health aspects (6664) 6664
young adult (6651) 6651
neoplasm metastasis (6608) 6608
paclitaxel - administration & dosage (6578) 6578
dose-response relationship, drug (6507) 6507
adenocarcinoma - drug therapy (6476) 6476
antineoplastic agents - administration & dosage (6383) 6383
antineoplastic agents (6265) 6265
drug therapy (6031) 6031
risk factors (5983) 5983
apoptosis (5912) 5912
carboplatin - administration & dosage (5847) 5847
deoxycytidine - administration & dosage (5811) 5811
methotrexate - administration & dosage (5709) 5709
antimitotic agents (5659) 5659
recurrence (5571) 5571
combination (5523) 5523
paclitaxel (5523) 5523
expression (5513) 5513
neoplasms - drug therapy (5484) 5484
neoadjuvant therapy (5421) 5421
lung neoplasms - pathology (5383) 5383
antineoplastic agents - pharmacology (5297) 5297
clinical trials (5297) 5297
disease progression (5263) 5263
colorectal neoplasms - drug therapy (5161) 5161
cancer therapies (5030) 5030
fluorouracil (5026) 5026
prednisone - administration & dosage (5022) 5022
doxorubicin (4965) 4965
phase-ii (4964) 4964
ovarian neoplasms - drug therapy (4899) 4899
kaplan-meier estimate (4890) 4890
cyclophosphamide (4829) 4829
infant (4682) 4682
antineoplastic agents - adverse effects (4663) 4663
lymphatic metastasis (4614) 4614
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (119145) 119145
Japanese (8343) 8343
French (2345) 2345
German (2230) 2230
Chinese (1962) 1962
Russian (1166) 1166
Spanish (838) 838
Italian (571) 571
Polish (546) 546
Hungarian (254) 254
Dutch (136) 136
Czech (109) 109
Romanian (56) 56
Ukrainian (50) 50
Hebrew (48) 48
Danish (45) 45
Bulgarian (39) 39
Portuguese (39) 39
Korean (37) 37
Serbian (33) 33
Finnish (28) 28
Croatian (23) 23
Norwegian (21) 21
Slovak (12) 12
Swedish (12) 12
Lithuanian (8) 8
Turkish (7) 7
Bosnian (4) 4
Afrikaans (2) 2
Arabic (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


JAMA : the journal of the American Medical Association, ISSN 0098-7484, 06/2017, Volume 317, Issue 23, pp. 2392 - 2401
IMPORTANCE: Combining biologic monoclonal antibodies with chemotherapeutic cytotoxic drugs provides clinical benefit to patients with advanced or metastatic... 
MEDICINE, GENERAL & INTERNAL | LEUCOVORIN | FIRE-3 | THERAPY | FOLFIRI PLUS CETUXIMAB | PHASE-II | IRINOTECAN | OXALIPLATIN | FLUOROURACIL | TUMORS | PROGRESSION | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Bevacizumab - therapeutic use | United States | Bevacizumab - adverse effects | Colorectal Neoplasms - genetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents - therapeutic use | Cetuximab - therapeutic use | Cetuximab - adverse effects | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Antineoplastic Agents - adverse effects | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Angiogenesis Inhibitors - therapeutic use | Adult | Camptothecin - administration & dosage | Female | Angiogenesis Inhibitors - adverse effects | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Camptothecin - adverse effects | Kaplan-Meier Estimate | Treatment Outcome | Canada | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Colorectal Neoplasms - secondary | Aged | Genes, ras | Organoplatinum Compounds - adverse effects | Chemotherapy | Usage | Care and treatment | Research | Colorectal cancer | Cancer | Drugs | Medical research | Colorectal carcinoma | Clinical trials | Cytotoxicity | Patients | Survival | K-Ras protein | Bevacizumab | Metastases | Survival analysis | Irinotecan | Randomization | Oxaliplatin | Monoclonal antibodies | Tumors
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2014, Volume 371, Issue 23, pp. 2167 - 2177
... than standard chemotherapy in patients with ALK -positive lung cancer. Rearrangements of the anaplastic lymphoma kinase ( ALK... 
CRITERIA | MEDICINE, GENERAL & INTERNAL | GEFITINIB | THERAPY | CISPLATIN | ADENOCARCINOMA | PHASE-III | KINASE | ANAPLASTIC LYMPHOMA | QLQ-C30 | PLUS | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Guanine - analogs & derivatives | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Protein Kinase Inhibitors - adverse effects | Cisplatin - administration & dosage | Pyridines - adverse effects | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Pyrazoles - adverse effects | Pyridines - therapeutic use | Kaplan-Meier Estimate | Carboplatin - administration & dosage | Adenocarcinoma - drug therapy | Carcinoma, Non-Small-Cell Lung - mortality | Pemetrexed | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Glutamates - administration & dosage | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Adenocarcinoma - mortality | Guanine - administration & dosage | Crizotinib | Treatment outcome | Chemotherapy | Usage | Care and treatment | Lung cancer | Analysis | Dosage and administration | Comparative analysis | Risk factors | Cancer | Appetite | Edema | Inhibitor drugs | Intravenous administration | Biomedical research | Diarrhea | Non-small cell lung carcinoma | Fatigue | Nausea | Metastasis | Patients | Cisplatin | Quality of life | Lungs | Platinum | Vomiting | Comparative studies | Carboplatin
Journal Article
Cancer Treatment Reviews, ISSN 0305-7372, 2014, Volume 40, Issue 9, pp. 1080 - 1088
Highlights • PTCL has a poor prognosis; existing therapies are insufficient. • We summarize current evidence on novel therapies for relapsed/refractory PTCL. •... 
Hematology, Oncology and Palliative Medicine | Antifolate | Nucleoside analog | Histone deacetylase inhibitor | Fusion protein | Peripheral T-cell lymphoma | Immunomodulatory agent | DENILEUKIN DIFTITOX | NON-HODGKINS-LYMPHOMAS | FOLLOW-UP | BRENTUXIMAB VEDOTIN SGN-35 | OPEN-LABEL | ALLOGENEIC TRANSPLANTATION | SINGLE-AGENT | PHASE-II TRIAL | ONCOLOGY | SALVAGE THERAPY | HIGH-DOSE CHEMOTHERAPY | Doxorubicin - therapeutic use | Humans | Recombinant Fusion Proteins - therapeutic use | Interleukin-2 - therapeutic use | Neoplasm Recurrence, Local - drug therapy | Antineoplastic Agents - therapeutic use | Cyclophosphamide - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Folic Acid Antagonists - therapeutic use | Stem Cell Transplantation | Topoisomerase Inhibitors - pharmacology | Thalidomide - analogs & derivatives | Diphtheria Toxin - therapeutic use | Topoisomerase Inhibitors - therapeutic use | Immunoconjugates - therapeutic use | Antineoplastic Agents - pharmacology | Depsipeptides - therapeutic use | Prednisolone - therapeutic use | Lymphoma, T-Cell, Peripheral - drug therapy | Antibodies, Monoclonal, Humanized - therapeutic use | Alemtuzumab | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Lymphoma, T-Cell, Peripheral - pathology | Vincristine - therapeutic use | Histone Deacetylase Inhibitors - therapeutic use | Lymphoma, T-Cell, Peripheral - therapy | Thalidomide - therapeutic use | Folic Acid Antagonists - pharmacology | Care and treatment | Lymphomas | T cells | Health aspects
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2012, Volume 379, Issue 9828, pp. 1791 - 1799
Summary Background The intensity of chemotherapy and need for additional radiotherapy in patients with advanced stage Hodgkin's lymphoma has been unclear... 
Internal Medicine | Radiotherapy Dosage | Doxorubicin/adverse effects | Etoposide/adverse effects | Procarbazine/adverse effects | Prospective Studies | Hodgkin Disease/drug therapy | Humans | Middle Aged | Proportional Hazards Models | Male | Treatment Outcome | Positron-Emission Tomography | Antineoplastic Combined Chemotherapy Protocols/adverse effects | Prednisone/adverse effects | Treatment Failure | Adolescent | Survival Analysis | Adult | Female | Cyclophosphamide/adverse effects | Vincristine/adverse effects | Neoplasm Staging | Bleomycin/adverse effects | SURVIVAL | ABVD | MEDICINE, GENERAL & INTERNAL | COMBINATIONS | POSITRON-EMISSION-TOMOGRAPHY | DISEASE | PROGNOSTIC SCORE | RISK | STANFORD-V | PROGRESSION | MOPP/ABV HYBRID | Doxorubicin - therapeutic use | Hodgkin Disease - pathology | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Hodgkin Disease - radiotherapy | Bleomycin - therapeutic use | Hodgkin Disease - drug therapy | Etoposide - adverse effects | Prednisone - adverse effects | Etoposide - therapeutic use | Bleomycin - adverse effects | Procarbazine - adverse effects | Procarbazine - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Vincristine - therapeutic use | Vincristine - adverse effects | Doxorubicin - adverse effects | Prednisone - therapeutic use | Chemotherapy | Usage | Care and treatment | PET imaging | Diagnosis | Hodgkin's disease | Cancer | Medical imaging | Meetings | Patient safety | Oncology | Lymphomas | Histology | Radiation therapy | Ovarian cancer
Journal Article
The lancet oncology, ISSN 1470-2045, 2017, Volume 18, Issue 7, pp. 874 - 886
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2014, Volume 32, Issue 13, pp. 1302 - 1308
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2016, Volume 375, Issue 19, pp. 1823 - 1833
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2018, Volume 378, Issue 22, pp. 2078 - 2092
Journal Article